Moderate hepatic impairment roughly doubled zavegepant exposure but this was not clinically meaningful, and no dose adjustment is needed for patients with mild or moderate liver disease.
No dose adjustment neededDespite ~2-fold increased drug exposure in moderate hepatic impairment, intranasal zavegepant was well-tolerated and no dosing modification is required
What the researchers found
In 8 participants with moderate hepatic impairment (Child-Pugh 7-9) versus 8 matched healthy controls, a single 10-mg intranasal zavegepant dose showed approximately 2-fold increase in total AUC0-inf (GLSM ratio 193%, 90% CI: 112-333) and 16% increase in Cmax (GLSM ratio 116%, 90% CI: 69-195). Unbound zavegepant showed similar patterns (~2.3-fold AUC increase, 39% Cmax increase). The unbound fraction was similar between groups (0.13 vs 0.11).
Only one treatment-emergent adverse event (mild headache) occurred, in a healthy participant. These changes were not considered clinically meaningful, supporting no dose adjustment for mild or moderate hepatic impairment.
Why it matters
Migraine patients often have comorbidities including liver disease, and many drugs require dose adjustments for hepatic impairment. This study confirms that zavegepant — the first intranasal CGRP receptor antagonist — can be used at standard doses in patients with liver disease, expanding its clinical utility. For the growing class of CGRP-targeted migraine therapies, knowing which patients need dose modifications is essential for safe prescribing.
How the study worked
Phase I pharmacokinetic study comparing a single 10-mg intranasal dose of zavegepant in 8 participants with moderate hepatic impairment (Child-Pugh score 7-9) versus 8 matched participants with normal hepatic function. Both total and unbound plasma zavegepant concentrations were measured. Safety was assessed through adverse event monitoring.
What this study cannot tell us
The study included only 16 participants (8 per group), which is standard for hepatic impairment PK studies but limits statistical power. Only moderate hepatic impairment was studied — severe impairment data is absent. The study used a single dose, so the effects of repeated dosing in hepatic impairment are unknown. The findings are specific to intranasal delivery and may not apply to other formulations.
How to read the evidence
This is a Phase I pharmacokinetic study published in Clinical and Translational Science. The design follows standard regulatory guidelines for hepatic impairment studies. While small (n=16), this is the accepted methodology for determining dose adjustments in special populations.
When this study was published
Published in 2024, this is a recent pharmacokinetic study supporting the clinical use of zavegepant, which received FDA approval in 2023 as the first intranasal CGRP receptor antagonist for acute migraine.
The bigger picture
CGRP receptor antagonists (gepants) are a newer class of migraine treatments alongside CGRP monoclonal antibodies. As these drugs become mainstream, pharmacokinetic studies in special populations (liver disease, kidney disease, elderly) are essential for safe prescribing. Zavegepant's favorable profile in hepatic impairment adds to its clinical appeal, particularly for patients who cannot use triptans due to cardiovascular contraindications.
Questions still open
- Is zavegepant safe in severe hepatic impairment, or would dose adjustment be needed in that population?
- How does repeated zavegepant dosing in liver-impaired patients affect drug accumulation and safety over time?
- Do other CGRP antagonists (gepants) show similar pharmacokinetic profiles in hepatic impairment?
Common questions
What is zavegepant and how is it different from CGRP antibodies?
Why does liver disease affect how drugs work in the body?
Read the original research
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.
Clinical and translational science, 17(7), e13813
Citation
Bhardwaj, Rajinder; Donohue, Mary K; Madonia, Jennifer; Morris, Beth; Marbury, Thomas C; Matschke, Kyle T; Croop, Robert; Bertz, Richard; Liu, Jing. (2024). Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.. Clinical and translational science, 17(7), e13813. https://doi.org/10.1111/cts.13813